Corcept Therapeutics (CORT) Raw Materials (2012 - 2024)

Corcept Therapeutics (CORT) posted Raw Materials of $704000.0 for Q1 2024, down 58.22% sequentially from $1.7 million in Q4 2020.

Analysis

Corcept Therapeutics (CORT) Raw Materials (2012 - 2024) Analysis & Trends

Corcept Therapeutics has reported Raw Materials for 10 years, with the latest figure at $704000.0 in Q1 2024.

Quarterly Raw Materials changed N/A year-over-year to $704000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $704000.0 (changed N/A YoY) and the FY2020 annual result came in at $1.7 million, up 21.31% from the prior year.
Raw Materials eased to $704000.0 in Q1 2024 per CORT's latest filing, from $1.7 million in the prior quarter.
Over five years, Raw Materials peaked at $1.7 million in Q4 2020 and troughed at $704000.0 in Q1 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Corcept Therapeutics	11.76 Bn	11.46 Bn	252.09 Mn

Historic Data

Download Data